Status:
COMPLETED
A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Epilepsies, Partial
Eligibility:
All Genders
3+ years
Phase:
PHASE3
Brief Summary
Examine the safety and efficacy of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures
Eligibility Criteria
Inclusion
- Completion of study A9451162 (NCT00603473)
Exclusion
- Seizures related to drugs or acute medical illness
- History of any serious medical or psychiatric disorder
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00620555
Start Date
May 1 2008
End Date
December 1 2010
Last Update
February 3 2021
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Obu-shi,Morioka-machi, Aichi-ken, Japan
2
Pfizer Investigational Site
Jonan-ku, Fukuoka, Japan
3
Pfizer Investigational Site
Kobe, Hyōgo, Japan
4
Pfizer Investigational Site
Suma-Ku,Kobe, Hyōgo, Japan